Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average – Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.78 and traded as low as $0.76. Vaxart shares last traded at $0.77, with a volume of 1,120,717 shares traded.

Analysts Set New Price Targets

Separately, Oppenheimer started coverage on shares of Vaxart in a research report on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price target on the stock.

Vaxart Stock Performance

The stock’s 50-day moving average is $0.84 and its 200-day moving average is $0.77. The company has a market cap of $136.60 million, a price-to-earnings ratio of -1.67 and a beta of 0.66.

Vaxart (NASDAQ:VXRT) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The company had revenue of $6.40 million for the quarter, compared to analyst estimates of $65.70 million. Vaxart had a negative net margin of 543.21% and a negative return on equity of 114.19%. During the same quarter in the previous year, the firm earned ($0.16) EPS. As a group, analysts predict that Vaxart, Inc. will post -0.47 EPS for the current year.

Institutional Trading of Vaxart

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mesirow Financial Investment Management Inc. grew its stake in shares of Vaxart by 100.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 20,000 shares in the last quarter. Tidal Investments LLC bought a new stake in shares of Vaxart in the 1st quarter worth $56,000. Sequoia Financial Advisors LLC bought a new stake in shares of Vaxart in the 2nd quarter worth $65,000. Monaco Asset Management SAM bought a new stake in shares of Vaxart in the 2nd quarter worth $402,000. Finally, Millennium Management LLC grew its stake in shares of Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.